Absci vs Ovid Therapeutics
Ovid Therapeutics is the larger business, with $7.3m of revenue in fiscal 2025 against $2.8m for Absci (2.6 times as much). Ovid Therapeutics grew faster (1181.3% against -38.2%). Ovid Therapeutics kept more of each dollar of sales as profit: a net margin of -240.1% against -4113.7%. Ovid Therapeutics carries less debt relative to equity (0.0% against 0.5%).
| Latest fiscal year | AbsciABSI, 2025 | Ovid TherapeuticsOVID, 2025 |
|---|---|---|
| Revenue | $2.8m | $7.3m |
| Revenue growth | -38.2% | 1181.3% |
| Net income | −$115m | −$17.4m |
| Operating margin | -4297.0% | -585.2% |
| Net margin | -4113.7% | -240.1% |
| Return on equity | -62.5% | -17.5% |
| Free cash flow | −$94.0m | −$38.3m |
| Cash | $20.0m | $13.2m |
| Total debt | $873,000 | $0 |
| Debt to equity | 0.5% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 140 | 23 |
| Market value | $1.57bn | $446m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 10 (Weak) |
| Insider trades, 12 months | 5 buys, 2 sales | 0 buys, 2 sales |